Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 244.07 Million USD | 10.36% |
| 2022 | 221.15 Million USD | 8.31% |
| 2021 | 204.18 Million EUR | -13.26% |
| 2020 | 235.38 Million EUR | 70.11% |
| 2019 | 138.37 Million EUR | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 180.05 Million EUR | 72.38% |
| 2016 | 104.45 Million EUR | 182.34% |
| 2015 | 36.99 Million EUR | 17.58% |
| 2014 | 31.46 Million EUR | -13.68% |
| 2013 | 36.45 Million EUR | 12.52% |
| 2012 | 32.39 Million EUR | -3.43% |
| 2011 | 33.54 Million EUR | -7.23% |
| 2010 | 36.15 Million EUR | -40.72% |
| 2009 | 60.99 Million EUR | -35.76% |
| 2008 | 94.94 Million EUR | 17.27% |
| 2007 | 80.96 Million USD | 109.82% |
| 2006 | 38.58 Million EUR | 457.08% |
| 2005 | 6.92 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 205.96 Million USD | -12.54% |
| 2024 Q3 | 199.72 Million USD | -3.03% |
| 2024 Q1 | 235.5 Million USD | -6.53% |
| 2023 Q1 | 223.65 Million USD | 1.13% |
| 2023 Q3 | 226.52 Million USD | -1.27% |
| 2023 Q2 | 229.43 Million USD | 2.58% |
| 2023 FY | 244.07 Million USD | 10.36% |
| 2023 Q4 | 251.96 Million USD | 11.23% |
| 2022 Q3 | 182.06 Million USD | -6.26% |
| 2022 Q4 | 221.15 Million USD | 21.47% |
| 2022 FY | 221.15 Million USD | 8.31% |
| 2022 Q1 | 198.77 Million USD | -5.39% |
| 2022 Q2 | 194.22 Million USD | -2.29% |
| 2021 Q2 | 213.77 Million EUR | -4.11% |
| 2021 Q3 | 207.21 Million EUR | -3.07% |
| 2021 Q4 | 210.1 Million EUR | 1.39% |
| 2021 FY | 204.18 Million EUR | -13.26% |
| 2021 Q1 | 222.93 Million EUR | -5.14% |
| 2020 Q1 | 207.69 Million EUR | 49.93% |
| 2020 FY | 235.38 Million EUR | 70.11% |
| 2020 Q4 | 235.01 Million EUR | 9.33% |
| 2020 Q3 | 214.96 Million EUR | 0.84% |
| 2020 Q2 | 213.17 Million EUR | 2.64% |
| 2019 Q4 | 138.52 Million EUR | -2.86% |
| 2019 Q1 | 146.54 Million EUR | -16.25% |
| 2019 Q2 | 145.88 Million EUR | -0.45% |
| 2019 FY | 138.37 Million EUR | 0.0% |
| 2019 Q3 | 142.6 Million EUR | -2.25% |
| 2018 Q3 | 167.95 Million EUR | 3.25% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | 174.96 Million USD | 4.17% |
| 2018 Q2 | 162.68 Million EUR | -5.12% |
| 2018 Q1 | 171.46 Million EUR | -4.77% |
| 2017 Q1 | 109.53 Million EUR | 4.86% |
| 2017 FY | 180.05 Million EUR | 72.38% |
| 2017 Q4 | 180.05 Million EUR | 14.66% |
| 2017 Q3 | 157.03 Million EUR | 14.21% |
| 2017 Q2 | 137.5 Million EUR | 25.54% |
| 2016 Q3 | 38 Million EUR | -3.79% |
| 2016 Q1 | 39.37 Million EUR | 6.42% |
| 2016 Q2 | 39.5 Million EUR | 0.33% |
| 2016 Q4 | 104.45 Million EUR | 174.84% |
| 2016 FY | 104.45 Million EUR | 182.34% |
| 2015 FY | 36.99 Million EUR | 17.58% |
| 2015 Q3 | 41.16 Million EUR | 64.82% |
| 2015 Q4 | 36.99 Million EUR | -10.13% |
| 2015 Q2 | 24.97 Million EUR | -5.79% |
| 2015 Q1 | 26.5 Million EUR | -15.75% |
| 2014 FY | 31.46 Million EUR | -13.68% |
| 2014 Q4 | 31.46 Million EUR | -0.34% |
| 2014 Q3 | 31.57 Million EUR | -19.66% |
| 2014 Q2 | 39.29 Million EUR | 9.51% |
| 2014 Q1 | 35.88 Million EUR | -1.56% |
| 2013 Q2 | 38.14 Million EUR | -15.91% |
| 2013 Q4 | 36.45 Million EUR | 6.73% |
| 2013 FY | 36.45 Million EUR | 12.52% |
| 2013 Q3 | 34.15 Million EUR | -10.46% |
| 2013 Q1 | 45.36 Million EUR | 40.02% |
| 2012 Q3 | 34.36 Million EUR | 0.0% |
| 2012 Q1 | 41.69 Million EUR | 24.29% |
| 2012 Q4 | 32.39 Million EUR | -5.72% |
| 2012 FY | 32.39 Million EUR | -3.43% |
| 2011 FY | 33.54 Million EUR | -7.23% |
| 2011 Q3 | 34.68 Million EUR | -6.79% |
| 2011 Q1 | 34.72 Million EUR | -3.97% |
| 2011 Q2 | 37.21 Million EUR | 7.17% |
| 2011 Q4 | 33.54 Million EUR | -3.29% |
| 2010 Q2 | 74 Million EUR | -0.76% |
| 2010 FY | 36.15 Million EUR | -40.72% |
| 2010 Q1 | 74.57 Million EUR | 22.27% |
| 2010 Q4 | 36.15 Million EUR | -27.15% |
| 2010 Q3 | 49.63 Million EUR | -32.94% |
| 2009 FY | 60.99 Million EUR | -35.76% |
| 2009 Q4 | 60.99 Million EUR | 0.0% |
| 2008 FY | 94.94 Million EUR | 17.27% |
| 2007 FY | 80.96 Million USD | 109.82% |
| 2006 FY | 38.58 Million EUR | 457.08% |
| 2005 FY | 6.92 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -889605.829% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -2478.439% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -236.787% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -30077.4% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4556.105% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -313.585% |
| Qrons Inc. | 1.48 Million USD | -16294.899% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -19804.617% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -225.778% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -545973.474% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1634.43% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -357.88% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -2447.197% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -57796.472% |
| SQZ Biotechnologies Company | 50.03 Million USD | -387.766% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1932.457% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -6237.214% |
| Mesoblast Limited | 188.44 Million USD | -29.52% |
| Marizyme, Inc. | 26.67 Million USD | -814.963% |
| Genus plc | 485 Million USD | 49.676% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4077.457% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -12042.15% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -9599.57% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -6322.974% |
| ContraFect Corporation | 32.53 Million USD | -650.278% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -12218.781% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -6276.579% |
| IMV Inc. | 37.93 Million USD | -543.435% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1972.245% |
| MultiCell Technologies, Inc. | 1617.67 USD | -15087835.117% |
| ONE Bio Corp. | 27.49 Million USD | -787.673% |
| Accustem Sciences Inc. | 1.07 Million USD | -22515.287% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -215.271% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -11439.718% |
| Q BioMed Inc. | 8.13 Million USD | -2901.043% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -194.294% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -4642.933% |
| Biomind Labs Inc. | 1.49 Million USD | -16186.604% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -105.583% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -2599.267% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1226.238% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -16922.082% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -171667.48% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -121259.315% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -4147.835% |
| GB Sciences, Inc. | 5.41 Million USD | -4405.223% |
| Alpha Cognition Inc. | 7.16 Million USD | -3306.569% |
| HST Global, Inc. | 593.59 Thousand USD | -41017.904% |
| CSL Limited | 18.62 Billion USD | 98.689% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -19283.288% |
| Halberd Corporation | 728.71 Thousand USD | -33393.432% |
| Enzolytics Inc. | 365.26 Million USD | 33.18% |
| Agentix Corp. | 2.51 Million USD | -9621.874% |
| Resverlogix Corp. | 67.39 Million USD | -262.148% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -29000.237% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 45.146% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -14139.965% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -886.312% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1950.499% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -6559.265% |
| AVAX Technologies, Inc. | 3.99 Million USD | -6011.382% |
| Zenith Capital Corp. | 27.56 Thousand USD | -885216.841% |
| Genscript Biotech Corporation | 1.32 Billion USD | 81.592% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -102170.651% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -6435.967% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -35749.12% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -8900.933% |
| Kadimastem Ltd | 3.5 Million USD | -6863.831% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -364574.506% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -385.582% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1434.6% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -52422.816% |
| LadRx Corporation | 2.2 Million USD | -10991.565% |
| Cell Source, Inc. | 15.8 Million USD | -1444.11% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4372.154% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4372.154% |
| NovAccess Global Inc. | 7.86 Million USD | -3004.965% |
| Affymax, Inc. | 8.87 Million USD | -2651.358% |
| Itoco Inc. | 1.65 Million USD | -14664.108% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -11796.918% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -3934.931% |
| Mobile Lads Corp. | 1.31 Million USD | -18481.923% |
| CytoDyn Inc. | 127.89 Million USD | -90.84% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -583820.668% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -15482.009% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -2109.748% |
| SYBLEU INC | 681.41 Thousand USD | -35718.659% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -3899.948% |
| International Stem Cell Corporation | 5.27 Million USD | -4525.223% |
| Bioxytran, Inc. | 3.24 Million USD | -7411.094% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -38901.197% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -5186.255% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -495.358% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -996.218% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -11950.685% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -4355.513% |
| Neutra Corp. | 973.52 Thousand USD | -24970.953% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -741.196% |
| PureTech Health plc | 125.58 Million USD | -94.352% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -6396.27% |
| IXICO plc | 1.9 Million USD | -12743.973% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1088.918% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -136.221% |
| CSL Limited | 18.62 Billion USD | 98.689% |
| Cellectis S.A. | 249.36 Million USD | 2.124% |